| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| US20845100P | 2000-05-31 | 2000-05-31 | |
| US60/208,451 | 2000-05-31 | ||
| US63119100A | 2000-08-02 | 2000-08-02 | |
| US09/631,191 | 2000-08-02 | ||
| PCT/US2001/017391WO2001092549A2 (en) | 2000-05-31 | 2001-05-30 | Method and composition for targeting an adenoviral vector | 
| Publication Number | Publication Date | 
|---|---|
| AU2001265154A1true AU2001265154A1 (en) | 2001-12-11 | 
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| AU2001265154AAbandonedAU2001265154A1 (en) | 2000-05-31 | 2001-05-30 | Method and composition for targeting an adenoviral vector | 
| Country | Link | 
|---|---|
| US (1) | US20030099619A1 (en) | 
| EP (1) | EP1301612A2 (en) | 
| JP (1) | JP2003534806A (en) | 
| AU (1) | AU2001265154A1 (en) | 
| WO (1) | WO2001092549A2 (en) | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US8071740B2 (en)* | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | 
| GB0112652D0 (en)* | 2001-05-24 | 2001-07-18 | Inst Of Molecul & Cell Biology | Internalisation of virus into cells | 
| CA2487811A1 (en) | 2002-05-27 | 2003-12-04 | Per Sonne Holm | Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors | 
| AU2003240281A1 (en) | 2002-06-14 | 2003-12-31 | Case Western Reserve University | Cell targeting methods and compositions | 
| DE602004032330D1 (en)* | 2003-02-17 | 2011-06-01 | Fuso Pharmaceutical Ind | NOVEL VIRUS VECTOR | 
| US20040166091A1 (en)* | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear | 
| US20060263336A1 (en)* | 2003-03-24 | 2006-11-23 | Caplan Arnold I | Cell targeting methods and compositions | 
| JP2007527206A (en)* | 2003-04-04 | 2007-09-27 | ユニバーシティ オブ ローザンヌ | Peptabody for cancer treatment | 
| EP1649028B1 (en)* | 2003-07-25 | 2012-08-22 | Genvec, Inc. | Adenoviral vector-based vaccines | 
| FR2860004A1 (en)* | 2003-09-18 | 2005-03-25 | Roussy Inst Gustave | Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus | 
| US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses | 
| DE602004025726D1 (en) | 2003-11-14 | 2010-04-08 | Genvec Inc | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF LOCALLY ADVANCED PRIMARY INOPERABLES PANCREATIC CARCINOMA (LAPC). | 
| AU2005243730B2 (en) | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response | 
| JP4787936B2 (en)* | 2004-05-26 | 2011-10-05 | サイオクサス セラピューティクス リミティド | Chimeric adenovirus for use in cancer treatment | 
| US7776322B2 (en)* | 2004-08-16 | 2010-08-17 | Stefan Kochanek | Modified viral vector particles | 
| JP2008511336A (en)* | 2004-09-01 | 2008-04-17 | アメリカ合衆国 | Methods for using adenoviral vectors with increased immunogenicity in vivo | 
| US7556808B2 (en)* | 2004-12-16 | 2009-07-07 | Philadelphia Health And Education Corporation | Dual inhibitors of HIV-1 gp-120 interactions | 
| BRPI0615400A2 (en) | 2005-08-31 | 2011-05-17 | Genvec Inc | adenoviral vector-based malaria vaccines | 
| EP1951297A2 (en) | 2005-11-10 | 2008-08-06 | GenVec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine | 
| WO2007094653A1 (en)* | 2006-02-13 | 2007-08-23 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles. | 
| US20100210478A1 (en)* | 2006-06-29 | 2010-08-19 | Xiaolian Gao | Make and use of surface molecules of varied densities | 
| US9193790B2 (en)* | 2006-12-07 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of antagonists of the interaction between HIV GP120 and A4B7 integrin | 
| WO2008086386A2 (en)* | 2007-01-09 | 2008-07-17 | Genvec, Inc. | Adenoviral vector-based malaria vaccines | 
| EP2224946B1 (en) | 2007-12-28 | 2016-11-02 | Kalos Therapeutics, Inc. | Anti-proliferative compounds and their use | 
| GB0803076D0 (en)* | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof | 
| KR101154374B1 (en)* | 2009-02-18 | 2012-07-09 | 재단법인 아산사회복지재단 | Composition Comprising Adeno-Associated Virus Serotype 5 Vector for Targeted Gene Delivery | 
| US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins | 
| WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines | 
| EA201270607A1 (en) | 2009-11-09 | 2012-09-28 | Генвек, Инк. | MONKEY MONKEY ADENOVIRUS AND METHODS FOR USING IT | 
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine | 
| WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions | 
| US8920813B2 (en) | 2010-12-20 | 2014-12-30 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine | 
| WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors | 
| KR102089121B1 (en) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Oncolytic adenovirus compositions | 
| DK3021859T3 (en) | 2013-10-25 | 2018-03-05 | Psioxus Therapeutics Ltd | ONCOLYTIC ADENOVIRA EQUIPPED WITH HETEROLOGICAL GENES | 
| TWI710635B (en) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | Adenoviral vector encoding human atonal homolog-1 (hath1) | 
| HUE048320T2 (en) | 2015-04-30 | 2020-07-28 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein | 
| AU2016369485B2 (en) | 2015-12-17 | 2024-02-01 | Akamis Bio Limited | Group B adenovirus encoding an anti-TCR-complex antibody or fragment | 
| AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics | 
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics | 
| SMT202300106T1 (en) | 2016-03-31 | 2023-05-12 | Centre Nat Rech Scient | Adenoviral coat protein derived delivery vehicles | 
| JP2019532621A (en) | 2016-08-29 | 2019-11-14 | サイオクサス セラピューティクス リミテッド | Adenovirus armed with a bispecific T cell engager (BiTE) | 
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus | 
| WO2018064523A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells | 
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof | 
| US20210139932A1 (en)* | 2017-05-03 | 2021-05-13 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells | 
| EP3775175A4 (en) | 2018-04-09 | 2022-02-09 | Salk Institute for Biological Studies | COMPOSITIONS OF ONCOLYTIC ADENOVIRUS WITH INCREASED REPLICATION PROPERTIES | 
| CN118767143A (en) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | Compositions and methods for preventing and treating hearing loss | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US4593002A (en)* | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins | 
| US4578079A (en)* | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide | 
| US4792525A (en)* | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide | 
| US5166320A (en)* | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells | 
| US5223409A (en)* | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins | 
| US5663143A (en)* | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase | 
| NZ244306A (en)* | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation | 
| US5981273A (en)* | 1991-09-30 | 1999-11-09 | Boehringer Ingelheim Int'l. Gmbh | Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells | 
| US5521291A (en)* | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells | 
| US5270170A (en)* | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method | 
| SE503225C2 (en)* | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antibody complex for introduction of virus into mammalian cells | 
| GB9223084D0 (en)* | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells | 
| US5981505A (en)* | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material | 
| US5593972A (en)* | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization | 
| DE4311651A1 (en)* | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells | 
| US5543328A (en)* | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins | 
| US5443953A (en)* | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates | 
| US5783386A (en)* | 1994-02-24 | 1998-07-21 | Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. | Mycobacteria virulence factors and a novel method for their identification | 
| US5559099A (en)* | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same | 
| US5770442A (en)* | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same | 
| US5703057A (en)* | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization | 
| US5958672A (en)* | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms | 
| AUPN477695A0 (en)* | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy | 
| US5622699A (en)* | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo | 
| US5939250A (en)* | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis | 
| EP0866721A4 (en)* | 1995-12-08 | 2003-06-04 | Univ Alabama Birmingham Res Fo | Targeted adenovirus vectors | 
| US5955275A (en)* | 1997-02-14 | 1999-09-21 | Arcaris, Inc. | Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes | 
| US5922315A (en)* | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins | 
| EP0974668B1 (en)* | 1998-07-07 | 2002-10-02 | Transgene S.A. | Use of adenoviral E4 reading frames to improve expression of a gene of interest | 
| Publication number | Publication date | 
|---|---|
| EP1301612A2 (en) | 2003-04-16 | 
| WO2001092549A3 (en) | 2003-01-16 | 
| JP2003534806A (en) | 2003-11-25 | 
| US20030099619A1 (en) | 2003-05-29 | 
| WO2001092549A2 (en) | 2001-12-06 | 
| Publication | Publication Date | Title | 
|---|---|---|
| AU2001265154A1 (en) | Method and composition for targeting an adenoviral vector | |
| AU2001280968A1 (en) | Compositions and methods for directed gene assembly | |
| AU2001292836A1 (en) | Endoscopic targeting method and system | |
| AU2001271210A1 (en) | Method for virtual trading | |
| AU2001261566A1 (en) | Well service composition and method | |
| AU1340000A (en) | Novel adenoviral vector and methods for making and using the same | |
| AU2001239947A1 (en) | Methods and compositions for regulating adipocytes | |
| AU7068600A (en) | Encrypted coupons | |
| AU2778801A (en) | Antisense compositions and methods | |
| AU3420701A (en) | Method and apparatus for providing advertisements | |
| AU2001289205A1 (en) | System and method for tactical couponing | |
| AU2001253255A1 (en) | Compositions and methods for inhibiting gene expression | |
| AU2001271720A1 (en) | Methods and compositions for determining gene function | |
| AU2001280604A1 (en) | Compositions comprising icariside i and anhydroicaritin and methods for making the same | |
| AU2002327380A1 (en) | Cells and methods for propagating adenoviral vectors | |
| AU2001245987A1 (en) | Compositions and methods for gene therapy | |
| AU2001279850A1 (en) | Method and arrangement for studsystem | |
| AU2001232054A1 (en) | Vector | |
| AU2001238485A1 (en) | Methods and compositions for gene delivery | |
| AU2001233932A1 (en) | Method and composition | |
| AU2001288736A1 (en) | Method and composition for enhancing vision | |
| AU2002243285A1 (en) | Auxiliary metering apparatus and methods | |
| AU2001278802A1 (en) | System and method for autorizing e-commerce | |
| AU2001261513A1 (en) | Composition and method for increasing testosterone levels | |
| AU2001253481A1 (en) | Methods and compositions for eleciting an immune response |